

PRESS RELEASE

JHL Hosts Clinical Trial Investigator Meeting in Moscow for JHL1101 Clinical Trials

29JUN2017

JHL Biotech is announcing that it recently hosted an investigator meeting in Moscow, Russia for the Russian clinical investigators and study coordinators participating in JHL's ongoing JHL1101 Phase 1 clinical trial in patients with rheumatoid arthritis. 20 participants representing six of eight sites in Russia attended the meeting.

End

Media Contact:

Gregory Manker
Phone: +886-909-780-862
gmanker@jhlbiotech.com

About JHL Biotech

JHL Biotech Inc. (Stock Code: 6540.TWO) is a biopharmaceutical startup founded by a group of industry veterans with deep experience in pharmaceutical development and operations. JHL is backed by premier financial firms, including Kleiner Perkins Caufield & Byers, Sequoia Capital, Biomark Capital, Milestone Capital, Fidelity, and the China Development Industrial Bank. JHL Biotech's mission is to provide the world with low-cost medicines of exceptional quality. JHL is focused on research and development of new protein-based therapies and biosimilars. JHL Biotech has two world-class facilities built in accordance with United States, European Union, and ICH cGMP regulations and standards. For more information, please visit www.jhlbiotech.com.